E. Nikitina , O. Cheremisina , D. Kulbakin , N. Litviakov
{"title":"P100","authors":"E. Nikitina , O. Cheremisina , D. Kulbakin , N. Litviakov","doi":"10.1016/j.ejcsup.2015.08.071","DOIUrl":null,"url":null,"abstract":"<div><p>The purpose of the study was to access pattern of microRNA expression in tissue of precancerous lesions and larynx cancer.</p><p>A total of 25 people with a diagnosis of dysplasia II–III (<em>n</em> <!-->=<!--> <!-->10), control group (dysplasia 0, <em>n</em> <!-->=<!--> <!-->15) and larynx cancer patients (<em>n</em> <!-->=<!--> <!-->46) were examined. Fresh frozen biopsies and adjacent normal epithelium were used. The diagnosis was verified by histology. All qRT-PCR data were analyzed using the Pfaffl analysis. Multiplex RT-PCR on miRNA templates were performed as described by Chen et al. (2005). TaqMan miRNA assays (Iyevleva et al., 2012) were used to quantify expression of mature miRNAs of interest (miR-18a, -21, -155, -200a, -200c, -205, -221, -494). Data were analyzed using Welsh t-test with a 5% FDR correction. According to our results, aberrant expression of some miRNAs was showed. There was no significant differences in miRNA expression in a total group (<em>n</em> <!-->=<!--> <!-->25) although a trend towards overexpression of oncogenic miRNA-21 and -155 according to severity of dysplastic changes in a tissue were present. Detailed analysis showed significant overexpression of that miRNAs as well as miRNA-200c and -205 in a group of dysplasia II- III against control group (15 vs 10, <em>p</em> <!-->=<!--> <!-->0.019, <em>p</em> <!-->=<!--> <!-->0.045 and <em>p</em> <!-->=<!--> <!-->0.020, <em>p</em> <!-->=<!--> <!-->0.038, respectively) but these results did not meet 5% FDR correction.</p><p>Data showed overexpression of the same microRNA (-205, -155, -200 and -21) in larynx cancer patients compared to control group (46 vs 15, <em>p</em> <!-->=<!--> <!-->0.0002, <em>p</em> <!-->=<!--> <!-->0.008, <em>p</em> <!-->=<!--> <!-->0.009, <em>p</em> <!-->=<!--> <!-->0.013, respectively). It should be pointed that microRNA pattern both in larynx cancer and patients with dysplasia II-III was very close showing similarity of these groups at molecular level. Frequency of cases with microRNA-205 overexpression was 2.98 times higher in cancer patients than in those who had no malignant transformation (CI 95%, 1.41–16.26, <em>p</em> <!-->=<!--> <!-->0.007). Data showed that up regulation of microRNA-205 could be a marker of disease progression (OR<!--> <!-->=<!--> <!-->4.79). Three other microRNAs did not show any promising results as biomarkers of cancer progression but data obtained has interesting fundamental value.</p><p>These miRs (-21, -155, -205 and -200c) are known to be regulators of processes that play an emergent role in carcinogenesis and our results obtained in vivo highlight and expand knowledge about some aspects of larynx cell transformation. Data suggest that miRNAs changing its expression according to dysplasia progress and could be important players in complex process of carcinogenesis as well as could be potential markers of disease progression.</p></div>","PeriodicalId":11675,"journal":{"name":"Ejc Supplements","volume":"13 1","pages":"Page 40"},"PeriodicalIF":0.0000,"publicationDate":"2015-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ejcsup.2015.08.071","citationCount":"0","resultStr":"{\"title\":\"P100\",\"authors\":\"E. Nikitina , O. Cheremisina , D. Kulbakin , N. Litviakov\",\"doi\":\"10.1016/j.ejcsup.2015.08.071\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The purpose of the study was to access pattern of microRNA expression in tissue of precancerous lesions and larynx cancer.</p><p>A total of 25 people with a diagnosis of dysplasia II–III (<em>n</em> <!-->=<!--> <!-->10), control group (dysplasia 0, <em>n</em> <!-->=<!--> <!-->15) and larynx cancer patients (<em>n</em> <!-->=<!--> <!-->46) were examined. Fresh frozen biopsies and adjacent normal epithelium were used. The diagnosis was verified by histology. All qRT-PCR data were analyzed using the Pfaffl analysis. Multiplex RT-PCR on miRNA templates were performed as described by Chen et al. (2005). TaqMan miRNA assays (Iyevleva et al., 2012) were used to quantify expression of mature miRNAs of interest (miR-18a, -21, -155, -200a, -200c, -205, -221, -494). Data were analyzed using Welsh t-test with a 5% FDR correction. According to our results, aberrant expression of some miRNAs was showed. There was no significant differences in miRNA expression in a total group (<em>n</em> <!-->=<!--> <!-->25) although a trend towards overexpression of oncogenic miRNA-21 and -155 according to severity of dysplastic changes in a tissue were present. Detailed analysis showed significant overexpression of that miRNAs as well as miRNA-200c and -205 in a group of dysplasia II- III against control group (15 vs 10, <em>p</em> <!-->=<!--> <!-->0.019, <em>p</em> <!-->=<!--> <!-->0.045 and <em>p</em> <!-->=<!--> <!-->0.020, <em>p</em> <!-->=<!--> <!-->0.038, respectively) but these results did not meet 5% FDR correction.</p><p>Data showed overexpression of the same microRNA (-205, -155, -200 and -21) in larynx cancer patients compared to control group (46 vs 15, <em>p</em> <!-->=<!--> <!-->0.0002, <em>p</em> <!-->=<!--> <!-->0.008, <em>p</em> <!-->=<!--> <!-->0.009, <em>p</em> <!-->=<!--> <!-->0.013, respectively). It should be pointed that microRNA pattern both in larynx cancer and patients with dysplasia II-III was very close showing similarity of these groups at molecular level. Frequency of cases with microRNA-205 overexpression was 2.98 times higher in cancer patients than in those who had no malignant transformation (CI 95%, 1.41–16.26, <em>p</em> <!-->=<!--> <!-->0.007). Data showed that up regulation of microRNA-205 could be a marker of disease progression (OR<!--> <!-->=<!--> <!-->4.79). Three other microRNAs did not show any promising results as biomarkers of cancer progression but data obtained has interesting fundamental value.</p><p>These miRs (-21, -155, -205 and -200c) are known to be regulators of processes that play an emergent role in carcinogenesis and our results obtained in vivo highlight and expand knowledge about some aspects of larynx cell transformation. Data suggest that miRNAs changing its expression according to dysplasia progress and could be important players in complex process of carcinogenesis as well as could be potential markers of disease progression.</p></div>\",\"PeriodicalId\":11675,\"journal\":{\"name\":\"Ejc Supplements\",\"volume\":\"13 1\",\"pages\":\"Page 40\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.ejcsup.2015.08.071\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ejc Supplements\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1359634915000725\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ejc Supplements","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1359634915000725","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
本研究的目的是获取microRNA在癌前病变和喉癌组织中的表达模式。共检查诊断为II-III型发育不良的25例(n = 10),对照组(0例,n = 15)和喉癌患者(n = 46)。采用新鲜冷冻活检和邻近正常上皮。该诊断经组织学证实。所有qRT-PCR数据均采用Pfaffl分析。按照Chen等人(2005)的描述,对miRNA模板进行多重RT-PCR。TaqMan miRNA测定法(Iyevleva et al., 2012)用于量化感兴趣的成熟miRNA (miR-18a, -21, -155, -200a, -200c, -205, -221, -494)的表达。数据分析采用威尔士t检验,FDR校正为5%。根据我们的研究结果,一些mirna出现了异常表达。总的组(n = 25) miRNA表达没有显著差异,尽管根据组织中发育不良变化的严重程度存在致癌miRNA-21和-155的过表达趋势。详细分析显示,与对照组相比,II- III型发育不良组的miRNAs以及miRNA-200c和-205显著过表达(分别为15比10,p = 0.019, p = 0.045和p = 0.020, p = 0.038),但这些结果不符合5%的FDR校正。数据显示,与对照组相比,喉癌患者中相同的microRNA(-205, -155, -200和-21)过表达(分别为46 vs 15, p = 0.0002, p = 0.008, p = 0.009, p = 0.013)。需要指出的是,喉癌和II-III型发育不良患者的microRNA模式非常接近,在分子水平上具有相似性。microRNA-205在肿瘤患者中的过表达频率是未发生恶性转化患者的2.98倍(CI 95%, 1.41 ~ 16.26, p = 0.007)。数据显示,microRNA-205的上调可能是疾病进展的标志(OR = 4.79)。另外三种microrna作为癌症进展的生物标志物没有显示出任何有希望的结果,但获得的数据具有有趣的基础价值。已知这些miRs(-21、-155、-205和-200c)是在癌变过程中发挥紧急作用的过程的调节因子,我们在体内获得的结果突出并扩展了对喉部细胞转化某些方面的认识。数据表明,mirna根据发育不良的进展改变其表达,可能在复杂的癌变过程中发挥重要作用,也可能是疾病进展的潜在标志物。
The purpose of the study was to access pattern of microRNA expression in tissue of precancerous lesions and larynx cancer.
A total of 25 people with a diagnosis of dysplasia II–III (n = 10), control group (dysplasia 0, n = 15) and larynx cancer patients (n = 46) were examined. Fresh frozen biopsies and adjacent normal epithelium were used. The diagnosis was verified by histology. All qRT-PCR data were analyzed using the Pfaffl analysis. Multiplex RT-PCR on miRNA templates were performed as described by Chen et al. (2005). TaqMan miRNA assays (Iyevleva et al., 2012) were used to quantify expression of mature miRNAs of interest (miR-18a, -21, -155, -200a, -200c, -205, -221, -494). Data were analyzed using Welsh t-test with a 5% FDR correction. According to our results, aberrant expression of some miRNAs was showed. There was no significant differences in miRNA expression in a total group (n = 25) although a trend towards overexpression of oncogenic miRNA-21 and -155 according to severity of dysplastic changes in a tissue were present. Detailed analysis showed significant overexpression of that miRNAs as well as miRNA-200c and -205 in a group of dysplasia II- III against control group (15 vs 10, p = 0.019, p = 0.045 and p = 0.020, p = 0.038, respectively) but these results did not meet 5% FDR correction.
Data showed overexpression of the same microRNA (-205, -155, -200 and -21) in larynx cancer patients compared to control group (46 vs 15, p = 0.0002, p = 0.008, p = 0.009, p = 0.013, respectively). It should be pointed that microRNA pattern both in larynx cancer and patients with dysplasia II-III was very close showing similarity of these groups at molecular level. Frequency of cases with microRNA-205 overexpression was 2.98 times higher in cancer patients than in those who had no malignant transformation (CI 95%, 1.41–16.26, p = 0.007). Data showed that up regulation of microRNA-205 could be a marker of disease progression (OR = 4.79). Three other microRNAs did not show any promising results as biomarkers of cancer progression but data obtained has interesting fundamental value.
These miRs (-21, -155, -205 and -200c) are known to be regulators of processes that play an emergent role in carcinogenesis and our results obtained in vivo highlight and expand knowledge about some aspects of larynx cell transformation. Data suggest that miRNAs changing its expression according to dysplasia progress and could be important players in complex process of carcinogenesis as well as could be potential markers of disease progression.
期刊介绍:
EJC Supplements is an open access companion journal to the European Journal of Cancer. As an open access journal, all published articles are subject to an Article Publication Fee. Immediately upon publication, all articles in EJC Supplements are made openly available through the journal''s websites.
EJC Supplements will consider for publication the proceedings of scientific symposia, commissioned thematic issues, and collections of invited articles on preclinical and basic cancer research, translational oncology, clinical oncology and cancer epidemiology and prevention.
Authors considering the publication of a supplement in EJC Supplements are requested to contact the Editorial Office of the EJC to discuss their proposal with the Editor-in-Chief.
EJC Supplements is an official journal of the European Organisation for Research and Treatment of Cancer (EORTC), the European CanCer Organisation (ECCO) and the European Society of Mastology (EUSOMA).